Marketing: Page 2
-
CMS approves Michigan Medicaid drug value-based payment plan
Administrator Seema Verma also previewed forthcoming agency action on protected classes of drugs in Medicare Part D, hinting that CMS plans to further open the space to private negotiation.
By David Lim • Nov. 14, 2018
-
Pfizer launches biosimilar version of Amgen's Epogen
Retacrit's wholesale acquisition cost clocks in 57% lower than that of J&J's Procrit and 34% lower that of Amgen's Epogen.
By Jacob Bell • Nov. 14, 2018
-
Express Scripts plans 'Flex' formulary focused on authorized generics
Gilead’s generic versions of its own hepatitis C treatments Epclusa and Harvoni are first on the list for the new formulary, which starts Jan. 1.
By Kristin Jensen
-
Specialty drugs drive Rx spending increase, Blue Cross says
Insurers under the Blues' umbrella, which accounts for dozens of independently run payers, spent about $100 billion on prescription drugs in 2017.
By Andrew Dunn • Nov. 13, 2018
-
SponsoredHow do you energize your sales force?
Don't just assume your sales person will be motivated by more money. Extra compensation may not be the best answer and energy can play a big role.
By Steve Marley
-
UK calls Vertex on contentious Orkambi negotiations
A key committee has asked for more information from Vertex on its case for the cystic fibrosis drug, including the price offered to NHS.
By Suzanne Elvidge • Nov. 12, 2018
-
AstraZeneca calls victory in CV study, but will payers feel the same?
A large cardiovascular study found the British pharma's Farxiga offers heart health benefits, yet the diabetes drug still faces stiff competition.
By Jacob Bell • Nov. 12, 2018
-
Mylan, Theravance win FDA approval for COPD drug
The companies now face the daunting task of launching Yupelri into a market dominated by several heavyweight brands.
By Suzanne Elvidge • Nov. 12, 2018
-
UK's NICE gives early no to expanded use of AstraZeneca's Lynparza
In a draft decision, a committee for the U.K.'s cost watchdog recommended not providing coverage for expanded use of the PARP inhibitor in ovarian cancer.
By Andrew Dunn • Nov. 09, 2018
-
PARP makers search for a way to break through
Though Lynparza, Zejula and Rubraca saw growth in the third quarter, they've each had trouble breaking further into the ovarian cancer maintenance market.
By Jacob Bell • Nov. 08, 2018
-
Earnings reveal pharma's mixed feelings on Trump drug pricing proposal
A plan that would shake up how CMS pays for Medicare Part B drugs could leave the bottom lines of major players like Roche, Amgen and Bristol-Myers exposed, according to analysts.
By Jacob Bell • Nov. 07, 2018
-
Novartis gives up on biosimilar Rituxan in US
An additional ask from the FDA, which had rejected Novartis' copycat version earlier this year, seems to have changed the big pharma's thinking.
By Kristin Jensen
-
Lilly strengthens Trulicity's leading position with REWIND results
Wall Street analysts note data from the cardiovascular outcomes study could help differentiate the diabetes drug in the crowded GLP-1 market.
By Jacob Bell • Nov. 05, 2018
-
Humira biosimilar discounting 'aggressive' as competition enters in Europe
AbbVie, though, is confident it can deliver double-digit earnings growth in 2019 despite the biosimilar headwinds in Europe to Humira.
By Ned Pagliarulo • Nov. 02, 2018
-
Insulin drugmakers under scrutiny for pricing, patent practices
Reports from a Congressional caucus and a consumer group could fuel further criticism of the top diabetes pharma companies, in particular Sanofi.
By Andrew Dunn • Nov. 02, 2018
-
Gilead's stock wobbles on HIV pricing concerns
In a cost-saving effort, United Healthcare will offer patients who opt for cheaper HIV drugs prepaid debit cards, spurring concerns Gilead could be exposed to pricing pressures in HIV.
By Ned Pagliarulo • Nov. 01, 2018
-
Shingrix gives GSK a near-term boost
Questions on future growth still loom large, however, amid a pipeline revamp and competitive pressures in the pharma's core therapeutic areas.
By Ned Pagliarulo • Nov. 01, 2018
-
Novartis wins US nod for Humira biosimilar, but focus now on Europe
A settlement deal blocks market launch in the U.S. until 2023. In Europe, however, the battle for market share is just beginning.
By Ned Pagliarulo • Oct. 31, 2018
-
Come January, will pharma pricing pledges hold?
Pfizer CEO Ian Read indicated this week that the pharma, which rolled back some price hikes in July, would return to "business as normal" next year.
By Ned Pagliarulo • Oct. 31, 2018
-
Deep DiveRed pill or blue? It could be a billion-dollar decision
Viagra and Nexium underscore how marketers and manufacturers can use color to make a drug franchise more successful.
By Jacob Bell • Oct. 29, 2018
-
Amgen, Regeneron appear most at risk from Trump's latest pricing plan
Pharma hates the proposal to link Medicare Part B payments to international prices. But some drugmakers would stand to lose more than others.
By Ned Pagliarulo • Oct. 26, 2018
-
Trump pitches new plan to bring US drug prices down
The administration's latest effort will take aim at Medicare Part B, aiming to link drug payments in the U.S. to the prices pharmaceutical companies set abroad.
By Ned Pagliarulo , David Lim • UPDATED: Oct. 25, 2018 at 6:24 p.m.
-
FDA approves flu drug with new mechanism of action
Just in time for the flu season, the newly OK'd antiviral treatment could be the viral boost that Roche needs.
By Suzanne Elvidge • Oct. 25, 2018
-
Amgen cuts US Repatha price 60% amid market pressure
While effective, the cholesterol drug's $14,520 list price has been a tough pill to swallow for payers. Now, Amgen will cut the price to $5,850.
By Ned Pagliarulo , Jacob Bell • UPDATED: Oct. 24, 2018 at 7:15 p.m.
-
DTC's big issues: Trump, cancer drugs and the First Amendment
Direct-to-consumer drug advertising, while always controversial, looks set to become a battleground yet again.
By Ned Pagliarulo , Jacob Bell , Andrew Dunn • Oct. 24, 2018